6-chloro-3-(3-methoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazine | 596825-41-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-chloro-3-(3-methoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazine
• 英文别名: 6-Chloro-3-(3-methoxyphenyl)[1,2,4]triazolo[4,3-b]pyridazine
• CAS: 596825-41-1
• 化学式: C₁₂H₉ClN₄O
• mdl: MFCD11540514
• 分子量: 260.683
• InChiKey: KBPDGUHMZTUSRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-chloro-3-(3-methoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazine 、 环丙胺 反应 4.0h， 生成 N-cyclopropyl-3-(3-methoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-amine
  参考文献：
  名称：

  Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase

  摘要：

  A series of substituted 3-aryl-6-amino-triazolo[4,3-b]pyridazines were identified as highly selective inhibitors of Pim-1 kinase. Initial exploration identified compound 24 as a potent, selective inhibitor, limited in its utility by poor solubility and permeability. Understanding the unusual ATP-binding site of the Pim kinases and X-ray crystallographic data on compound 24 led to design improvements in this class of inhibitor. This resulted in compound 29, a selective, soluble and permeable inhibitor of Pim-1. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.061
• 作为产物：
  描述：

  在 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 16.0h， 生成 6-chloro-3-(3-methoxyphenyl)-[1,2,4]triazolo[4,3-b]pyridazine
  参考文献：
  名称：

  Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase

  摘要：

  A series of substituted 3-aryl-6-amino-triazolo[4,3-b]pyridazines were identified as highly selective inhibitors of Pim-1 kinase. Initial exploration identified compound 24 as a potent, selective inhibitor, limited in its utility by poor solubility and permeability. Understanding the unusual ATP-binding site of the Pim kinases and X-ray crystallographic data on compound 24 led to design improvements in this class of inhibitor. This resulted in compound 29, a selective, soluble and permeable inhibitor of Pim-1. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.061

文献信息

• TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF
  申请人：SOUTHERN RESEARCH INSTITUTE

  公开号：US20130296298A1

  公开（公告）日：2013-11-07

  The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors.

  本发明提供了新型LRRK2激酶抑制剂，并使用这些抑制剂治疗疾病状态的方法。
• MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines
  作者：Leslie N. Aldrich、Evan P. Lebois、L. Michelle Lewis、Natalia T. Nalywajko、Colleen M. Niswender、C. David Weaver、P. Jeffrey Conn、Craig W. Lindsley

  DOI：10.1016/j.tetlet.2008.10.127

  日期：2009.1

  General, high-yielding MAOS protocols for the expedient synthesis of functionalized 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines are described amenable to an iterative analog library synthesis strategy for the lead optimization of an M1 antagonist screening hit. Optimized compounds proved to be highly selective M1 antagonists.

  描述了用于功能化 3,6-二取代-[1,2,4] 三唑并 [4,3- b ] 哒嗪的便利合成的通用、高产 MAOS 协议，该协议适用于先导优化的迭代类似物库合成策略M1 拮抗剂筛选命中。经优化的化合物被证明是高度选择性的 M1 拮抗剂。
• US9187484B2
  申请人：——

  公开号：US9187484B2

  公开（公告）日：2015-11-17
• [EN] TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDAZINE, UTILISATION COMME INHIBITEURS DE LA KINASE LRRK2, ET PROCÉDÉS POUR LEUR PRÉPARATION
  申请人：SOUTHERN RES INST

  公开号：WO2013166276A1

  公开（公告）日：2013-11-07

  The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Certain triazolopyridazine compounds have been discovered according to the present disclosure that inhibit LRRK2, and therefore find utility in the treatment of a number of disorders neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy.